Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
Launched by WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY · Apr 18, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to help doctors find and remove meningiomas, which are tumors that occur in the membranes surrounding the brain and spinal cord. Researchers want to see if a special injection called [Cu64]DOTATATE, followed by using a gamma probe device during surgery, can effectively detect these tumors. The goal is to improve the accuracy of tumor removal during surgery, which could lead to better outcomes for patients.
The trial is currently looking for participants aged 18 to 99 who have a strong suspicion of having a meningioma based on MRI scans or previous surgery reports. However, pregnant or breastfeeding individuals, those undergoing certain types of surgery where the gamma probe can't be used, and patients with specific medical conditions or treatments may not be eligible. If you join the study, you can expect to receive the injection before your surgery, and the medical team will monitor how well the gamma probe can help locate the tumor. This research could potentially lead to improved techniques for treating meningiomas in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • High suspicion of meningioma necessitating surgical resection based on conventional MRI criteria, or diagnosis of meningioma based on pathology reports from prior resection with radiographic findings of suspected recurrent or residual tumor necessitating repeat surgery.
- Exclusion Criteria:
- • Pregnant or breastfeeding
- • Patients undergoing endoscopic endonasal resection, eyebrow incision surgery, or any surgical procedure in which the neoprobe cannot be employed
- • Patients with hypersensitivity to somatostatin analogs
- • Patients with contraindications to conventional MRI
- • Patients with prior history of cranial radiation therapy
- • Patients currently enrolled in other therapeutic clinical trials related to meningioma will be excluded
About Weill Medical College Of Cornell University
Weill Medical College of Cornell University is a leading academic institution dedicated to advancing medical research and education. As a prominent sponsor of clinical trials, it focuses on innovative healthcare solutions and the development of new therapies across various medical disciplines. The institution is committed to fostering collaborative research efforts that enhance patient care and improve health outcomes. With a robust infrastructure and a team of experienced researchers and clinicians, Weill Cornell aims to translate scientific discoveries into practical applications, ensuring a strong emphasis on ethical standards and regulatory compliance throughout the clinical trial process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Jana Ivanidze, MD/PhD
Principal Investigator
Weill Medical College of Cornell University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported